| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.78 | 3.68 | 1.16 | 3.32 | 4.24 | 1.07 | 1.94 | 4.30 | 6.03 | 10.07 | 3.02 | — |
| Quick Ratio | 0.78 | 3.68 | 1.16 | 3.32 | 4.24 | 1.07 | 1.94 | 4.30 | 6.03 | 10.07 | 3.02 | — |
| Debt / Equity | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.14 | — | — |
| ROE | -143.57% | -148.57% | 1880.80% | -192.12% | -361.95% | -3467.11% | 409.05% | 204.93% | 122.85% | -182.45% | -936.93% | 355.41% |
| ROA | -109.87% | -108.59% | -672.13% | -142.09% | -282.79% | -310.60% | 199.35% | 157.44% | 102.16% | -139.48% | -186.22% | 62.54% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — |
| Book Value / Share | 0.44 | 0.78 | -0.13 | 0.24 | 0.41 | 0.03 | 0.76 | 0.26 | 0.55 | 0.44 | 0.01 | 0.02 |
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company focused on developing innovative therapeutics that aim to overcome both primary and acquired resistance to cancer immunotherapies. The company leverages its proprietary Immune Fx™ (IFx) technology platform, which harnesses the innate immune system by making tumor cells mimic bacteria to stimulate immune attack. Its lead candidate, IFx-2.0, targets aggressive skin cancers, including Merkel cell carcinoma, and is currently in a Phase 3 clinical trial. Additionally, TuHURA Biosciences develops bi-specific immune modulating antibody drug conjugates (ADCs) and antibody-peptide conjugates (APCs) targeting myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment to prevent immunosuppression and enhance checkpoint inhibitor effectiveness. The company also acquired TBS-2025, a VISTA-inhibiting monoclonal antibody for potential treatment of blood-related cancers such as acute myeloid leukemia. TuHURA’s integrated technologies address major challenges limiting the efficacy of immunotherapies, positioning it as a notable player in advancing cancer treatment modalities.